Gilead’s Biktarvy leads Q4 sales growth

Gilead Sciences (NASDAQ:GILD) Q4 results:

Revenues: $5,879M (+1.4%); product sales: $5,796M (+2.0%); HIV: $4,577M (+12.6%).

Key product sales: Biktarvy: $1,570 (+171.6%); Genvoya: $958M (-20.6%); Truvada: $768M (-6.7%); Odefsey: $435M (-2.9%); Descovy: $437M (+6.3%); Yescarta: $122M (+50.6%).

Net income: $2,696M (+999%); non-GAAP net income: $1,653M (-11.7%); EPS: $2.12 (+999%); non-GAAP EPS: $1.30 (-9.7%).

2020 guidance: Product sales: $21,800M – 22,200M; EPS: $5.15 – 5.55; non-GAAP EPS: $6.05 – 6.45.

Gilead Sciences EPS misses by $0.37, beats on revenue

https://seekingalpha.com/news/3538200-gileads-biktarvy-leads-q4-sales-growth